BACKGROUND: Pneumococcal infections are a significant cause of morbidity and mortality, and young infants are particularly vulnerable to infection. Maternal immunization can protect infants, but there are limited data on the duration of pneumococcal vaccine antibody in pregnant women. We report on maternal antibody concentrations one year after immunization with 23-valent pneumococcal polysaccharide (23vPPS) vaccine. METHOD: The Mother's Gift study randomly assigned 340 pregnant Bangladeshi mothers between ages 18 and 36 to receive eitherinactivated influenza vaccine (Fluarix(®)) or the 23vPPS vaccine (Pneumovax(®)) during the third trimester. Sera were collected before immunization, at delivery, and at one year post-delivery. We determined anti-capsular IgG antibody to 9 pneumococcal serotypes by a multiplex Luminex ELISA. We report antibody geometric mean concentrations (GMCs) for 9 serotypes, 12 month/delivery geometric mean ratios (GMRs) and proportions seroprotected (>0.35 mcg/mL) in 23vPPS vaccine recipients and controls at delivery and at 12 months. RESULTS: Among pneumococcal vaccinees, GMCs remained stable, with an overall 12 month/delivery GMR of 0.83 (95% CI, 0.75-0.92). In the control group, GMCs increased with a mean ratio of 1.98 (95% CI, 1.81-2.17; P<0.0001). GMCs in these vaccinees did not decline significantly in the 12 months after antenatal immunization. CONCLUSION:GMCs in these adult vaccinees and controls did not decline significantly in the 12 months after antenatal immunization. Interestingly, mothers who did not receive 23vPPS in pregnancy show a substantial increase of GMC for most serotypes in the first year after immunization. Further studies are needed to determine the need for repeat doses of 23vPPS vaccine in subsequent pregnancies more than a year later.
RCT Entities:
BACKGROUND:Pneumococcal infections are a significant cause of morbidity and mortality, and young infants are particularly vulnerable to infection. Maternal immunization can protect infants, but there are limited data on the duration of pneumococcal vaccine antibody in pregnant women. We report on maternal antibody concentrations one year after immunization with 23-valent pneumococcalpolysaccharide (23vPPS) vaccine. METHOD: The Mother's Gift study randomly assigned 340 pregnant Bangladeshi mothers between ages 18 and 36 to receive either inactivated influenza vaccine (Fluarix(®)) or the 23vPPS vaccine (Pneumovax(®)) during the third trimester. Sera were collected before immunization, at delivery, and at one year post-delivery. We determined anti-capsular IgG antibody to 9 pneumococcal serotypes by a multiplex Luminex ELISA. We report antibody geometric mean concentrations (GMCs) for 9 serotypes, 12 month/delivery geometric mean ratios (GMRs) and proportions seroprotected (>0.35 mcg/mL) in 23vPPS vaccine recipients and controls at delivery and at 12 months. RESULTS: Among pneumococcal vaccinees, GMCs remained stable, with an overall 12 month/delivery GMR of 0.83 (95% CI, 0.75-0.92). In the control group, GMCs increased with a mean ratio of 1.98 (95% CI, 1.81-2.17; P<0.0001). GMCs in these vaccinees did not decline significantly in the 12 months after antenatal immunization. CONCLUSION: GMCs in these adult vaccinees and controls did not decline significantly in the 12 months after antenatal immunization. Interestingly, mothers who did not receive 23vPPS in pregnancy show a substantial increase of GMC for most serotypes in the first year after immunization. Further studies are needed to determine the need for repeat doses of 23vPPS vaccine in subsequent pregnancies more than a year later.
Authors: Melissa J Whaley; Charles Rose; Joseph Martinez; Gouri Laher; Deborah L Sammons; Jerry P Smith; John E Snawder; Ray Borrow; Raymond E Biagini; Brian Plikaytis; George M Carlone; Sandra Romero-Steiner Journal: Clin Vaccine Immunol Date: 2010-03-24
Authors: M Santosham; J A Englund; P McInnes; J Croll; C M Thompson; L Croll; W P Glezen; G R Siber Journal: Pediatr Infect Dis J Date: 2001-10 Impact factor: 2.129
Authors: David Goldblatt; Mahein Hussain; Nick Andrews; Lindsey Ashton; Camilla Virta; Alessia Melegaro; Richard Pebody; Robert George; Anu Soininen; John Edmunds; Nigel Gay; Helena Kayhty; Elizabeth Miller Journal: J Infect Dis Date: 2005-06-23 Impact factor: 5.226
Authors: K Zaman; Eliza Roy; Shams E Arifeen; Mahbubur Rahman; Rubhana Raqib; Emily Wilson; Saad B Omer; Nigar S Shahid; Robert F Breiman; Robert E Breiman; Mark C Steinhoff Journal: N Engl J Med Date: 2008-09-17 Impact factor: 91.245
Authors: George R Siber; Ih Chang; Sherryl Baker; Philip Fernsten; Katherine L O'Brien; Mathuram Santosham; Keith P Klugman; Shabir A Madhi; Peter Paradiso; Robert Kohberger Journal: Vaccine Date: 2007-02-21 Impact factor: 3.641
Authors: Beatriz P Quiambao; Hanna M Nohynek; Helena Käyhty; Jukka P Ollgren; Lorena S Gozum; Connie P Gepanayao; Victoria C Soriano; Pirjo Helena Makela Journal: Vaccine Date: 2007-03-28 Impact factor: 3.641
Authors: Godwin Enwere; Ekow Biney; Yin Bun Cheung; Syed M A Zaman; Brown Okoko; Claire Oluwalana; Adeola Vaughan; Brian Greenwood; Richard Adegbola; Felicity T Cutts Journal: Pediatr Infect Dis J Date: 2006-08 Impact factor: 2.129
Authors: Richard H Beigi; Kimberly B Fortner; Flor M Munoz; Jeff Roberts; Jennifer L Gordon; Htay Htay Han; Greg Glenn; Philip R Dormitzer; Xing Xing Gu; Jennifer S Read; Kathryn Edwards; Shital M Patel; Geeta K Swamy Journal: Clin Infect Dis Date: 2014-12-15 Impact factor: 9.079